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Abstract The recent literature on the putative involvement of a
single cycle of peroxisomal L-oxidation of 24:5n-6 and 24:6n-3
polyunsaturated fatty acids in the biosynthesis of the respective
docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) fatty
acids is critically reviewed. Present evidence suggests that in vitro
data in support of the above proposition is an artifact of a low
2,4-dienoyl-CoA reductase activity due to depletion of NADPH
resulting from incubation conditions. Kinetic studies with
radiolabeled precursors in cell cultures have shown lower initial
rates of labeling of 24:6n-3 than that of 22:6n-3, indicating that
24:6n-3 is an elongation product of 22:6n-3 rather than its
precursor. Analysis of other literature data supports the proposal
that 22:5n-6 and 22:6n-3 are synthesized in mitochondria via
channeled carnitine-dependent pathways involving separate n-6-
and n-3-specific desaturases. It is proposed that impaired
peroxisomal function in some peroxisomal disorders is a
secondary consequence of defective mitochondrial synthesis of
22:6n-3; moreover, some disorders of peroxisomal L-oxidation
show normal or increased 22:5n-6 concentrations, indicating that
22:5n-6 is synthesized by independent desaturases without
peroxisomal involvement.
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1. Introduction
More than 30 years ago Holman and Hofstetter [1] found
24:4n-6 to be a major constituent of neutral lipids in bovine
testes. A few years later, Carpenter [2] and Bridges and Co-
niglio [3] con¢rmed the presence of 24:4n-6 in rat testes and
also described the presence of 24:5n-6 in this tissue, which was
also found to accumulate in neutral lipids [2]. In addition to
the more likely possibility that 24:5n-6 is formed by a two-
carbon elongation of 22:5n-6, Bridges and Coniglio [3] pro-
posed that 24:5n-6 might also arise via a v6-desaturation of
24:4n-6. Voss et al. [4] have revived and expanded this pro-
posal more than two decades later in an attempt to explain
the di⁄culties in demonstrating in vitro microsomal v4-de-
saturation for the synthesis of 22:5n-6 and 22:6n-3. In their
putative pathway, the intermediates 22:4n-6 and 22:5n-3
would be biosynthesized by the conventionally accepted mi-
crosomal scheme involving the alternative v6- and v5-desatu-
ration-elongation reactions, with the same desaturases pre-
sumably acting on both the n-3 and n-6 fatty acid series.
However, instead of a v4-desaturation, microsomes would
elongate the above docosapolyenoic fatty acid intermediates
by a two-carbon unit to 24:4n-6 and 24:5n-3, respectively,
which would then undergo a second v6-desaturation to form
24:5n-6 or 24:6n-3. At this stage, these 24-carbon fatty acids
would be transported to peroxisomes to undergo a putative
single cycle of peroxisomal L-oxidation to produce the ¢nal
respective 22:5n-6 and 22:6n-3 fatty acids.
2. Experiments with peroxisomal incubations
There are a number of problems with the above proposal.
Peroxisomes are known to readily L-oxidize 22:6n-3 to 20:5n-
3 [5^7], and diets rich in 22:6n-3 are known to produce per-
oxisomal proliferation [8,9] ; it is also known that 22:5n-6 is L-
oxidized to 20:4n-6 [10^13], presumably by the same L-oxida-
tion machinery. Therefore, for the involvement of peroxiso-
mal L-oxidation in the synthesis of 22:5n-6 from 24:5n-6 to be
a viable mechanism, it would be necessary to demonstrate that
the L-oxidation of 22:5n-6 is slow compared to that of 24:5n-
6. In an in vitro cell-free system containing mostly micro-
somes and peroxisomes, Mohammed et al. [14] claim to dem-
onstrate that 24:5n-6 primarily undergoes a single cycle of L-
oxidation in peroxisomes, to preferentially produce 22:5n-6.
The explanation o¡ered for this ¢nding is that the NADPH-
dependent 2,4-dienoyl-CoA reductase, an auxiliary peroxiso-
mal enzyme needed to allow the L-oxidation of polyunsatu-
rated fatty acids in which the ¢rst double bond at position 4
(such as 22:5n-6 or 22:6n-3) is rate-limiting; thus, when
24:5n-6 undergoes the ¢rst L-oxidation cycle to produce a
fatty acid with a double bond at the 4th carbon, i.e. 22:5n-
6, a larger molar fraction of this fatty acid would move out of
the peroxisomes relative to the fraction that is further L-oxi-
dized. Indeed, these authors did ¢nd a limited activity of the
NADPH-dependent 2,4-dienoyl-CoA reductase in their in vi-
tro system. Although their incubation system contained
NADPH, a closer examination of their experimental condi-
tions reveals that their system also included pyruvate and
lactate dehydrogenase; these reactants are added to maintain
a low steady concentration of NADH, and as an NAD re-
generating device to drive the peroxisomal L-oxidation of sat-
urated fatty acids in in vitro systems [15]. Although it is
conventionally assumed that lactate dehydrogenase is speci¢c
for NADH, this speci¢city is only relative and some isozymes
appear to prefer NADPH as the electron donor [16^19].
Therefore, it is likely that most of the added NADPH was
actually oxidized to NADP under the above assay condi-
tions, and the apparent low NADPH-dependent 2,4-dienoyl-
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CoA reductase activity was an artifactual consequence of the
resulting low NADPH concentration; Mohammed et al. [14]
did not provide any data to show that the concentration of
NADPH was not a¡ected by the addition of exogenous lac-
tate dehydrogenase and pyruvate. There is clear evidence from
other sources that peroxisomes contain a very active 2,4-di-
enoyl-CoA reductase which is involved in the L-peroxidation
of 22:6n-3 and 22:5n-6; when peroxisomes are incubated with
0.1 mM NADPH (half of the concentration that Mohammed
et al. [14] used) or exogenous NADP-dependent isocitrate
dehydrogenase (to regenerate NADPH using endogenous iso-
citrate) the L-oxidation of 22:6n-3 is increased by 300% [20],
demonstrating that the 2,4-dienoyl-CoA reductase is not rate-
limiting when it has access to normal concentrations of
NADPH [5,6]. Therefore, we would predict that if Mo-
hammed et al. [14] were to add exogenous isocitrate and
NADP-speci¢c isocitrate dehydrogenase to their incubation
medium they would observe a rapid L-oxidation of 22:5n-6.
Mohammed et al. [14] also provide other data that cast
further doubt on the role of 24-carbon fatty acids in the syn-
thesis of 22:5n-6; the putative v6-desaturase substrate, i.e.
24:4n-6, is rapidly L-oxidized by peroxisomes under their con-
ditions. This loss of 24:4n-6 must necessarily greatly diminish
its desaturation to 24:5n-6, and if this destruction of the v6-
desaturase substrate occurs in vivo, the putative microsomal-
peroxisomal pathway would be an ine⁄cient pathway of
22:5n-6 synthesis indeed. The artifactual production of fatty
acid synthesis from manipulation of in vitro conditions of L-
oxidation enzymes would not be new; back in the late 1950’s
when it was proposed that fatty acid synthesis occurred by
reversal of L-oxidation, Seubert et al. [21] were able to manip-
ulate in vitro NAD/NADH and NADP/NADPH concen-
trations by exogenous dehydrogenases to show fatty acid syn-
thesis with some of the enzymes of the L-oxidation pathway,
even though it was later shown that fatty acid synthesis in
vivo occurs via an entirely di¡erent and e⁄cient pathway
now known as the multifunctional fatty acid synthetase.
3. Biosynthetic studies with cell cultures
Kinetic experiments with radiolabeled precursors in cell cul-
tures have also produced data that are not compatible with
the hypothesis that 24:5n-6 and 24:6n-3 are direct precursors
of 22:5n-6 and 22:6n-6, respectively. When human skin ¢bro-
blasts are incubated with [1-14C]20:5n-3, 22:6n-3 is labeled 48
h before any labeled 24:6n-3 is detected [22]. Similarly, when
Y79 retinoblastoma cells are incubated with [1-14C]20:4n-6,
22:5n-6 is labeled 24 h before any labeled 24:5n-6 can be
detected [22]. Additional experiments with Y79 retinoblasto-
ma cells clearly con¢rm these ¢ndings. Pulse-chase experi-
ments with [1-14C]20:5n-3 show a rapid labeling of 22:5n-3,
followed by 22:6n-3 which gained label at the same rate as
label loss from 22:5n-3; labeling of 24:6n-3 was much lower
and decreased very slowly over the entire chase period, while
24:5n-3 showed the least labeling and this remained essentially
steady over the course of the chase period [23]. The slower
labeling of the 24-carbon fatty acids at all times strongly
supports the contention that 24:5n-3 and 24:6n-3 are the elon-
gation products of 22:5n-3 and 22:6n-3, respectively, rather
than their precursors. Moreover, the lesser rate of labeling of
24:5n-3 than 24:6n-3, concomitantly with no loss of label
from 24:5n-3, is not compatible with 24:5n-3 being the pre-
cursor of 24:6n-3 as required by the putative microsomal v6-
desaturation of 24:5n-3; however, this metabolic inactivity
would be expected for dead-end elongation products. Addi-
tional experiments with ¢sh primary hepatocytes incubated
with [1-14C]18:3n-3 also show a precursor-product cross-
over between 22:5n-3 and 22:6n-3, with no label incorpora-
tion into 24:5n-3, while labeling of 24:6n-3 lags far behind
that of 22:6n-3 at all time points [24]; these data indicate
that the 24-carbon fatty acids are not precursors of 22:6n-3.
Other evidence not consistent with the proposal that 24:6n-3
is the direct precursor of 22:6n-3 has been obtained in kinetic
experiments with retinal tissue. When retinal pigment epithe-
lium is incubated with [3-14C]22:5n-3, labeled 22:6n-3 is
formed faster than 24:6n-3 during the ¢rst hours of incuba-
tion [25]. These data, again, are not consistent with these 24-
carbon fatty acids being precursors of 22:6n-3, but the other
way around. Other evidence inconsistent with the operation of
the putative microsomal-peroxisomal pathway has previously
been reviewed [26].
4. Evidence from peroxisomal disorders
Zellweger syndrome and several other peroxisomal disor-
ders are associated with very low concentrations of 22:6n-3
in brain and other tissues [27^29], and these data have been
cited as evidence in support of the putative involvement of
peroxisomal L-oxidation in the synthesis of 22:6n-3 [4,30].
However, the original cytological description of Zellweger
syndrome explicitly detailed a profound impairment of both
mitochondrial and peroxisomal functions [31] ; indeed, mito-
chondrial dysfunction was later found to be a characteristic of
these diseases [32^35]. These observations led Gold¢scher [36]
to suggest that peroxisomal dysfunction may be secondary to
a primary mitochondrial lesion in Zellweger syndrome. Pa-
tients with other disorders of peroxisomal L-oxidation, such
as pseudo-Zellweger syndrome and neonatal adrenoleukodys-
trophy [37], provide further inconsistencies with the proposed
peroxisomal involvement in synthesis of docosapolyenoic fatty
acids; these patients have normal or increased brain concen-
trations of 22:5n-6 while showing very low levels of 22:6n-3
[28,29]. Contrary to the conventional view, these data clearly
indicate that 22:6n-3 and 22:5n-6 must be biosynthesized by
respective separate n-3- and n-6-speci¢c desaturases (which are
probably transcriptionally regulated), as previously proposed
[26,38], and clearly show that peroxisomes are not involved in
the biosynthesis of 22:5n-6, at least. Moreover, tissues from
Zellweger syndrome patients show no accumulation of the
putative direct precursors of 22:5n-6 and 22:6n-3, i.e. 24:5n-
6 and 24:6n-3 respectively [39], which violates one of the
predictions of the proposed microsomal-peroxisomal scheme.
Further, when these 24-carbon fatty acids are synthesized in
normal tissues they accumulate in the neutral lipid fraction
[1,2,6,40]. Since known dead-end elongation products, such as
20:3n-3, 22:3n-3, and 24:3n-3, are also known to accumulate
in this fraction [40] rather than in a metabolically active phos-
pholipid pool, these data further suggest that 24:5n-6 and
24:6n-3 are primarily dead-end elongation products of
22:5n-6 and 22:6n-3, respectively, rather than their precur-
sors. Additional evidence inconsistent with peroxisomal in-
volvement in polyenoic fatty acid metabolism is the ¢nding
that patients with Zellweger syndrome or peroxisomal bifunc-
tional enzyme de¢ciency (another peroxisomal disorder) show
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decreases in plasma 20:4n-6 in addition to decreased 22:6n-3
[41,42]; since peroxisomes are not implicated in 20:4n-6 syn-
thesis, decreases in this fatty acid cannot be explained by
peroxisomal L-oxidation defects.
Based on the hypothesis that much of the clinical pathology
observed in peroxisomal disorders could be explained by a
de¢ciency of 22:6n-3 [27,30], Martinez and collaborators pio-
neered the treatment of infants with peroxisomal disorders
using dietary administration of this fatty acid [43^45]. In ad-
dition to a striking clinical improvement after supplemental
22:6n-3, these patients showed a decrease in the erythrocyte
concentrations of 24:1n-9 and 26:1n-9 (which characteristi-
cally accumulate in disorders of impaired peroxisomal L-oxi-
dation), and an increase in plasmalogen synthesis [43^45]. The
observation that the peroxisomal functions of L-oxidation and
plasmalogen synthesis [46,47] improve after the administration
of 22:6n-3 clearly indicates that such impaired peroxisomal
activities in these patients are secondary consequences of de-
fective 22:6n-3 synthesis, and not the other way around. These
¢ndings have, therefore, led to the proposal that 22:6n-3-con-
taining phospholipids are required as speci¢c structural or
conformational cofactors for the functional assembly and in-
tegration of enzymes and receptor proteins into organelle
membranes, including peroxisomes [26].
5. Mitochondrial involvement in 22:5n-6 and 22:6n-3 synthesis
If microsomes lack signi¢cant v4-desaturation activity, and
the putative peroxisomal-dependent system is an artifact of in
vitro assay conditions, the puzzle remains how to account for
the active synthesis of 22:5n-6 and 22:6n-3 demonstrated in
intact cell systems [22^24]. One attractive alternative that ex-
plains the above inconsistencies is the postulation that the
synthesis of these fatty acids occurs in the outer mitochondrial
membrane via a channeled carnitine-dependent pathway in-
volving separate n-3- and n-6-speci¢c v4-desaturases (Fig. 1)
[26]. This mitochondrial system would be the primary syn-
thetic site for 22:5n-6, 22:6n-3, and 20:4n-6, while the micro-
somal pathways would act as compensatory-redundant sys-
tems synthesizing 20:4n-6, 22:5n-6 and 20:5n-3 (but not
22:6n-3) [26].
Jakobsson et al. [48] have obtained some of the best recent
evidence for mitochondrial synthesis of 22:6n-3; when pri-
mary rat hepatocytes were incubated with [1-14C]18:3n-3,
and the kinetics of label incorporation into 22:6n-3-containing
phospholipids was followed, the initial rate of labeling of mi-
tochondrial 22:6n-3-containing phosphatidylcholine (PC) was
about 30 times that of microsomal PC. These striking results
cannot be explained by peroxisomal or microsomal contami-
nation of mitochondria since their carefully isolated mito-
chondria showed only a 3% contamination with microsomes
and 7% with peroxisomes, while the puri¢ed microsomes only
had 0.5% and 2% contamination with mitochondria and per-
oxisomes, respectively. Studies in retinal photoreceptors with
labeled 22:6n-3 precursors have also shown a precursor-prod-
uct relationship between mitochondria and the outer segments
which are rich in 22:6n-3-containing phospholipids [49,50].
Other lines of evidence in support of mitochondrial synthesis
of 22:6n-3 have been discussed previously [26].
Other data consistent with a mitochondrial synthesis of
docosapolyenoic fatty acids can be found in experiments
with testicular tissue. In rat testes, sexual maturation produces
a pronounced increase in its characteristic 22:5n-6 containing
phospholipids [51,52]; however, this accumulation of 22:5n-6
is accompanied by striking decreases in microsomal v6- and
v5-desaturases [53^55] along with the expected disappearance
of their products, i.e. 18:3n-6 and 20:3n-6 [2]. Such increases
in testicular 22:5n-6 have been demonstrated to occur from in
situ synthesis [56] and not by liver export, since it is well
known that the liver does not synthesize signi¢cant concen-
trations of 22:5n-6, except under conditions of n-3 fatty acid
de¢ciency as a compensatory response to decreased 22:6n-3
concentrations [57]. These observations suggest that liver bio-
synthesis of 22:5n-6 is catalyzed by transcription of an n-6-
speci¢c v4-desaturase that is normally repressed by 22:6n-3 or
its upstream n-3 precursors; its mechanism of transcriptional
repression may be similar to the one described for the v9-
desaturase gene by n-6 fatty acids [58^60], whose expression
is known to be increased by n-6 fatty acid de¢ciency [61]. The
above data clearly indicate that 22:5n-6 in rat testes must be
biosynthesized from 18:2n-6 via a pathway that does not in-
volve the participation of microsomes. In addition, since the
conventional microsomal desaturation intermediates are not
observed during active synthesis of testicular 22:5n-6, we
would propose that this fatty acid is made via the channeled
mitochondrial pathway discussed above, which would include
an androgen-controlled, tissue- and n-6-speci¢c v4-desaturase
isozyme whose transcription is not repressed by 22:6n-3 or its
precursors; evidence consistent with this postulation is the
fact that testicular synthesis of 22:5n-6 in rats is not inhibited
by a diet containing 22:6n-3 and 20:5n-3 [2]. Vitamin E has
been implicated in fatty acid desaturation [38] ; because vita-
min E de¢ciency is associated with infertility and decreased
concentrations of 22:5n-6 in rat testes (reviewed in [38]), it is
likely that D-K-tocopherol or its quinone metabolites are spe-
ci¢c cofactors for the mitochondrial fatty acid desaturation-
elongation pathway located in the outer membrane. Consis-
tent with this postulation is the ¢nding that the mitochon-
drion is the organelle that contains the highest concentration
D-K-tocopherol [62,63], with its outer membrane fraction con-
taining most of this vitamin [64].
Further evidence consistent with a mitochondrial synthesis
of 22:5n-6 in the testes is the observation that Sertoli cells
show a much lower incorporation of exogenous labeled ace-
tate than labeled 18:2n-6 into 22:5n-6 [65] ; these results are
corroborated by other data showing low incorporation of
exogenous acetate into 22-carbon polyunsaturated fatty acids
in other tissues [66^68], while intramitochondrial acetate is
readily incorporated into these fatty acids (reviewed in [26]).
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Fig. 1. Fatty acid desaturation and elongation reactions of the pro-
posed mitochondrial pathways for the synthesis of n-6 and n-3 long-
chain polyunsaturated fatty acids. The essential features of these
pathways are: (i) acetate and long-chain fatty acid substrates are
transported into mitochondria as carnitine esters; (ii) separate de-
saturases and elongation enzymes are required for the n-6 and n-3
fatty acid series; and (iii) the v6 desaturation and elongation prod-
ucts are channeled. The channeled intermediates are indicated in pa-
rentheses.
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Similarly, lactate, as a source of intramitochondrial acetate
(via lactate and pyruvate dehydrogenases), greatly increases
the incorporation of [14C]18:3n-3 into 22:6n-3 in cultured
hepatocytes [69]; under these conditions, 20:5n-3 is labeled
at a higher rate than its upstream conventional microsomal
desaturation-elongation intermediates 18:4n-3 and 20:4n-3,
indicating that the proposed mitochondrial pathway operates
as a channeled system in which these intermediates remain
enzyme bound and are therefore not readily available to the
phospholipid acyltransferases (see Fig. 1). However, addition
of D-decanoylcarnitine (an acylcarnitine antagonist) alters this
labeling pattern such that 18:4n-3 and 20:4n-3 are labeled
before 20:5n-3, and the total label incorporation into 22:6n-
3 is decreased [69]; this alteration in labeling kinetics indicates
that, in the presence of D-decanoylcarnitine, the channeled
mitochondrial carnitine-dependent pathway is inhibited while
the conventional microsomal pathway remains operative.
The carnitine dependency of the mitochondrial pathway of
22:6n-3 synthesis may explain the decreased 22:6n-3 and in-
creased 22:5n-6 concentrations observed in tissues from pa-
tients with pseudo-Zellweger syndrome and neonatal adreno-
leukodystrophy, as indicated in Section 4. These patients are
a¡ected by mutations in some of the enzymes of the perox-
isomal L-oxidation pathway and display a smaller peroxiso-
mal population (reviewed in [26]). Since the accumulated fatty
acids and L-oxidation intermediates are known to be excreted
as carnitine esters [70^72], it is likely that the resulting second-
ary carnitine de¢ciency is the cause of impaired mitochon-
drial 22:6n-3 synthesis, which would be partially compensated
for by an increased expression of the carnitine-independent
microsomal pathway for 22:5n-6 synthesis in these two disor-
ders; defective 22:6n-3 synthesis would secondarily impair
peroxisomal assembly. The decrease in 22:6n-6 in Zellweger
patients might be due either to a primary defect in the mito-
chondrial desaturation-elongation pathway, or to a secondary
carnitine de¢ciency resulting indirectly from defects in some of
the genes governing the functional integration of peroxisomal
proteins leading to an accumulation of acyl-CoA’s; since tis-
sues from these Zellweger patients also show decreased levels
of 22:5n-6, they may additionally lack the genetic control
elements necessary for a compensatory increase in microsomal
22:5n-6. Recent metabolic studies performed with mice with a
disrupted acyl-CoA oxidase gene support the hypothesis of
secondary carnitine de¢ciency being implicated in peroxisomal
disorders. The acyl-CoA oxidase (ACOX) de¢cient mouse has
been developed as an animal model for neonatal adrenoleu-
kodystrophy; ACOX de¢cient homozygotes show a strikingly
reduced population of peroxisomes during the ¢rst 3^4
months of age coupled with severe microvesicular steatosis
and sterility; however, after 6^7 months of age these mice
demonstrate a spontaneous peroxisomal proliferation with a
concomitant disappearance of hepatic steatosis [73]. The ini-
tial steatosis and defective peroxisomal assembly observed in
the ACOX de¢cient mice are consistent with a resulting sec-
ondary carnitine de¢ciency, which would cause both impaired
mitochondrial L-oxidation and 22:6n-3 synthesis and could
consequently produce defective integration of peroxisomal
proteins. However, this physiological condition might trigger
an up-regulation of the carnitine synthetic pathway with in-
creased expression of mitochondrial acyl-carnitine transfer-
ases, which would eventually restore both mitochondrial L-
oxidation and 22:6n-3 synthesis ; this metabolic adaptation
might, in turn, resolve the hepatic steatosis and allow the
functional assembly of peroxisomes observed in the older an-
imals. Although the ACOX de¢cient mouse shares a common
enzymatic defect with human neonatal adrenoleukodystrophy,
these mice show markedly less clinical pathology [73] ; this
may well be due to the proposed compensatory systems dis-
cussed above; however, these metabolic adaptations based
upon genetic control elements appear to be lacking or greatly
reduced in the human disorder. As discussed in Section 4,
patients with Zellweger syndrome or peroxisomal bifunctional
enzyme defect show decreased serum concentrations of both
22:6n-3 and 20:4n-6; however, the reduction in 20:4n-6 is less
than that of 22:6n-3 [41,42]. This apparent discrepancy would
be a predictable consequence of an impaired mitochondrial
synthesis of both 22:6n-3 and 20:4n-6, accompanied by a
concomitant partial compensation of up-regulated microso-
mal synthesis of 20:4n-6. If this hypothesis proves to be cor-
rect, administration of carnitine as well as of 22:6n-3 and
20:4n-6 might be of therapeutic value in peroxisomal disor-
ders.
Biosynthesis of 22:6n-3 by some microorganisms provides
additional evidence that peroxisomes are not involved in its
synthesis. Recent data indicate that certain motile marine bac-
terial species are able to synthesize 22:6n-3; this biosynthetic
pathway appears to be channeled since their fatty acid com-
position reveals very low concentrations of 22:6n-3 precursors
[74,75]. Because prokaryotes do not contain cell organelles,
these bacteria must biosynthesize 22:6n-3 via a peroxisome-
independent pathway. One could contend that these marine
prokaryotes have a hitherto unknown pathway for the syn-
thesis of this fatty acid, di¡erent from eukaryotes. However,
since mitochondria appear to have evolved from endosymbi-
otic bacteria [76^78], mitochondria and bacteria may share the
same pathway of 22:6n-3 synthesis.
Some marine eukaryotic microalgae are also known to syn-
thesize signi¢cant concentrations of 22:6n-3-containing lipids
[79], and provide further evidence that mitochondria, rather
than peroxisomes, are responsible for this synthesis. Among
these unicellular eukaryotes, the dino£agellate Crypthecodi-
nium cohnii is known to contain a large concentration of
22:6n-3, particularly esteri¢ed to phospholipids [80]. This al-
gal species is able to synthesize 22:6n-3 from acetate by a
channeled pathway since labeled acetate is not signi¢cantly
incorporated into any of the upstream intermediates, and la-
beled exogenous intermediates are similarly not signi¢cantly
incorporated into 22:6n-3 [81]. Consistent with mitochondrial
synthesis of 22:6n-3 is the ¢nding that this algal species has
large numbers of mitochondria; however, it lacks morpholog-
ically detectable peroxisomes [82], and it does not L-oxidize
fatty acids longer than octanoate [81,83]. These data indicate
that Crypthecodinium cohnii lacks long-chain fatty acid L-ox-
idation (either mitochondrial or peroxisomal), and therefore
could not utilize peroxisomal L-oxidation in 22:6n-3 synthesis.
Interestingly, as with the above bacteria, these phytoplankton
species which synthesize 22:6n-3 are also motile [84,85], even
though most plant species do not make this fatty acid, sug-
gesting that phospholipids containing 22:6n-3 may play an
essential role in motility. Signi¢cantly, defects in human
sperm motility (asthenospermia) are associated with low levels
of 22:6n-3-containing phospholipids [86,87] ; conceivably, the
sterility of the 3^4 month old ACOX de¢cient mice, described
above, may also be due to 22:6n-3 de¢ciency, since, unlike
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rats, mice and human testes contain signi¢cant amounts of
22:6n-3 [56]. The recurrent association between 22:6n-3 and
motility is consistent with the previous postulation that 22:6n-
3-containing phospholipids are necessary structural or confor-
mational cofactors for fast-kinetics receptor-activated systems,
such as ion pumps and channels, which are the hallmarks of
excitatory and contractile cells [26,88]. Given the important
functions of 22:5n-6 and 22:6n-3, it is unlikely that nature
could not have evolved a more reliable and direct biosynthetic
pathway for these essential fatty acids than the ine⁄cient and
roundabout microsomal-peroxisomal scheme proposed by
Voss et al. [4].
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